Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cytek BiosciencesCTKB +0.53%71 Cash-to-Debt is 9.90 as of Jun. 2026, which is 47% below its 10-year median of 18.84. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.52 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Cytek Biosciences ranks better than 74.59% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cytek Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 9.90.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cytek Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Cytek Biosciences's Cash-to-Debt or its related term are showing as below:
CTKB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 9.54 Med: 18.84 Max: No Debt
Current: 9.9
During the past 7 years, Cytek Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 9.54. And the median was 18.84.
CTKB's Cash-to-Debt is ranked better than 74.59% of 846
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs CTKB: 9.90
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cytek Biosciences Cash-to-Debt Related Terms
Cytek Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Cytek Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a Cash-to-Debt of 9.90 as of Jun. 2026. This is 47% below median its historical median of 18.84. Over the past decade, Cytek Biosciences' Cash-to-Debt has ranged from 9.54 to 10,000.00. According to the industry distribution chart, Cytek Biosciences ranks #215 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 25.4%.
Is Cytek Biosciences' Cash-to-Debt too high?
Cytek Biosciences' current Cash-to-Debt of 9.90 is 47% below median its 10-year median of 18.84. Over the past 10 years, this metric has ranged from a low of 9.54 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. Cytek Biosciences' value of 9.90 is 489.3% above this industry median. Based on the distribution chart, Cytek Biosciences ranks #215 out of 846 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Cash-to-Debt compare to CERS and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #215 out of 846 companies for Cash-to-Debt. This puts Cytek Biosciences in the upper half of its industry. The industry median Cash-to-Debt is 1.68. Cytek Biosciences' value of 9.90 is 489.3% above this benchmark. Historically, Cytek Biosciences' own Cash-to-Debt has ranged from 9.54 to 10,000.00 over the past decade. While the company's 10-year median is 18.84 vs. the industry median of 1.68, Cytek Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Cash-to-Debt of 9.90 is 489.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Cash-to-Debt is 9.90, which is 47% below median its own 10-year median of 18.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.52, compared to a current price of $4.71 — trading 14.8% below its estimated fair value. The current Cash-to-Debt is 9.90, which is 47% below median its 10-year median of 18.84 and 489.3% above the Medical Devices & Instruments industry median of 1.68. Cytek Biosciences' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Cash-to-Debt is 9.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.71 is trading 14.8% below its estimated GF Value™ of $5.52.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Cash-to-Debt: 9.90 (47% below median its 10-year median of 18.84)
GF Value™: $5.52 vs. price of $4.71 (14.8% below fair value)
Industry Position: 489.3% above the Medical Devices & Instruments median (#215 of 846)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
